Condition
Myositis, Inclusion Body
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Mrioriented Muscle Biopsy
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 2 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Mrioriented Muscle Biopsy1
- Alemtuzumab1
Active Sponsors
- National Institute of Neurological Disorders and Stroke (NINDS)1
- URC-CIC Paris Descartes Necker Cochin1
- Assistance Publique - Hôpitaux de Paris1
Top Investigators
Assistance Publique - Hôpitaux de Paris
Related Conditions
- Myositis1
- Polymyositis1
- Dermatomyositis1